News

Acadia Pharmaceuticals is starting its Phase 3 HARMONY trial to evaluate Nuplazid (pimavanserin) as a treatment for hallucinations and delusions associated with dementia-related psychosis. Currently, there is no approved therapy for this condition. Acadia’s announcement comes in the wake of the U.S. Food and Drug Administration designating Nuplazid a Breakthrough…

In a discovery that might provide an entirely new angle to Alzheimer’s disease research, scientists have mapped lymphatic vessels to the outside of the brains of living humans. Because these vessels are the main route traveled by immune cells, the finding, described in the journal eLife, may allow scientists…

UsAgainstAlzheimer’s released a report showing that Alzheimer’s disease is both an urgent healthcare concern among older U.S. military veterans and a threat to the future of younger ones. Titled “Veterans and Alzheimer’s: Meeting the Crisis Head On,” the report highlights the unique risk factors veterans facee, including…

Clumps of the Alzheimer’s-related protein amyloid-beta in nerves around organs related to smell may explain why people in the early stages of the disease lose their ability to detect odors, a study reports. Researchers at the Daegu Gyeungbuk Institute of Science and Technology in South Korea also discovered that loss…

It’s easy to forget — or be reluctant — to take family photographs when a member of the family is struggling with Alzheimer’s disease. The daily challenges, the ups and downs, can take a huge toll on patients and caregivers alike. Still, it is still important to remember and…

A researcher at the Jackson Laboratory (JAX) in Maine has been awarded a five-year, $5.4 million grant to investigate why genetic mutations linked to Alzheimer’s disease (AD) — and found people with a family history of the disease — don’t always affect memory and cognition. Assistant professor Catherine Kaczorowski received the award from the National Institute on Aging,…

Axovant Sciences said its Phase 3 MINDSET clinical trial of the investigational therapy intepirdine did not meet the study’s primary goal. In the trial, patients received 35 mg of intepirdine and were assessed at 24 weeks for any changes in cognition scores or measures of daily living, using two tests: ADAS-Cog (Alzheimer’s…

Certain personality traits — like high levels of neuroticism and low conscientiousness — may be linked to a higher risk of Alzheimer’s disease and other forms of dementia, finds a study published in the journal JAMA Psychiatry. But people don’t develop these traits are during pre-symptomatic stages of the disease,…

Scientists are coming closer to understanding how the gene variant apolipoprotein E4 (ApoE4) raises the risk of Alzheimer’s disease. Blocking ApoE4 — one of several variants of the ApoE gene — in the brain may prevent cell death and inflammation and lead to a treatment for Alzheimer’s, concludes a study, “ApoE4…

AgeneBio has obtained a National Institute on Aging grant to conduct a Phase 3 clinical trial of AGB101 (levetiracetam), a compound intended to prevent people with mild memory impairment from developing Alzheimer’s disease. The agency, part of the National Institutes of Health (NIH), has been backing the potential therapy’s development for…